GLP1R and metabolic dysfunction-associated steatohepatitis: In addition, the GLP-1 receptor agonist, liraglutide, is being investigated in a phase 2 clinical trial in NASH patients, the Liraglutide Efficacy and Action in NASH (LEAN) study [210].